Clinical Trials
73 trialsTUD-APOLLO-064
Technische Universität Dresden
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
SDK Therapeutics, Inc.
LEAP
Harvard Medical School (HMS and HSDM)
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Eastern Cooperative Oncology Group
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
SWOG Cancer Research Network
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
APL0511
Gruppo Italiano Malattie EMatologiche dell'Adulto
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Children's Oncology Group
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
Mexico APL
Instituto Nacional de Cancerologia de Mexico
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
University of Maryland, Baltimore
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
M.D. Anderson Cancer Center
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Orsenix LLC
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Nohla Therapeutics, Inc.
Red Cell Transfusion Goals in Patients With Acute Leukemias
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Washington
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
A Safety Study of SGN-CD33A in AML Patients
Seagen Inc.
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
Alliance for Clinical Trials in Oncology
Cell Samples From Patients With Leukemia
Children's Oncology Group
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia
Children's Oncology Group
Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia
Children's Oncology Group
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
PETHEMA Foundation
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
PETHEMA Foundation
QOL-APL0512
Gruppo Italiano Malattie EMatologiche dell'Adulto
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Indiana University
Vorinostat in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
National Cancer Institute (NCI)
High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission
Memorial Sloan Kettering Cancer Center
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
Memorial Sloan Kettering Cancer Center
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
National Cancer Institute (NCI)
flt3L in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
National Cancer Institute (NCI)